Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require IOP lowering treatment.~* In the investigator's opinion, patient's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).~* In the investigator's opinion, both eyes can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog eye drops as the sole therapy if medication was taken as directed, or with SLT monotherapy.~Exclusion Criteria:~* History of previous laser trabeculoplasty~* History or evidence of complicated cataract surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant \[IOL\], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear \[with or without vitreous loss\], substantial iris trauma, etc) or history of phakic IOL insertion for refractive error correction~* Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within the 6 months prior to treatment~* Previous use of commercially available Bimatoprost SR; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye) (Type: EXPERIMENTAL): Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Selective laser trabeculoplasty (SLT) administered on Day 1 followed by up to three sham bimatoprost SR administrations.~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only).
- Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye) (Type: EXPERIMENTAL): Participants enrolled prior to implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to three bimatoprost SR 15 µg administrations.~Contralateral Eye: SLT administered on Day 1 followed by up to three sham bimatoprost SR administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2) and Week 32 (Cycle 3; participants who reach Week 32 prior to implementation of Protocol Amendment 3 only).
- Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye) (Type: EXPERIMENTAL): Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations.~Contralateral Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria are met.
- Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye) (Type: EXPERIMENTAL): Participants enrolled after implementation of Protocol Amendment 3 receive the following treatment in each eye:~Assigned Primary Eye: Sham SLT administered on Day 1 followed by up to two bimatoprost SR 10 µg administrations.~Contralateral Eye: SLT administered on Day 1 followed by up to two sham bimatoprost SR administrations.~Bimatoprost SR/sham bimatoprost SR is administered on Day 4 (Cycle 1) and at Week 16 (Cycle 2). After implementation of Protocol Amendment 6, Cycle 2 retreatment could occur after Week 16 and prior to Month 12 based on when retreatment criteria were met.

Based on this trial design, predict the completion outcome and termination type (if applicable).